Trial Profile
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Atherosclerosis; Coronary artery disease; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms GLAGOV; PROFICIO
- Sponsors Amgen
- 17 Oct 2021 Results of Meta-Analysis from eight randomized, double-blind, placebo-controlled studies assessing Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD published in the Pharmacotherapy
- 23 Oct 2018 Results published in the Journal of the American College of Cardiology
- 26 Mar 2018 According to an Amgen media release, new data from this study will be presented at the American College of Cardiology's 67th Annual Scientific Session (ACC.18).